Name | Puromycin aminonucleoside |
Synonyms | aminonucleoside aminonucleosidepuromycin stylomycinaminonucleoside Puromycin aminonucleoside 3'-amino-3'-deoxy-n,n-dimethyl-adenosin 6-DIMETHYLAMIN-9-[3'-AMINO-3'DEOXYRIBOSYL]-PURINE 6-(dimethylamino)-9-(3-amino-3-deoxy-beta-d-ribofuranosyl)purine 9-(3-amino-3-deoxy-beta-d-ribofuranosyl)-6-(dimethylamino)-9h-purine |
CAS | 58-60-6 |
EINECS | 200-388-3 |
InChIKey | RYSMHWILUNYBFW-GRIPGOBMSA-N |
Molecular Formula | C12H18N6O3 |
Molar Mass | 294.31 |
Density | 1.2131 (rough estimate) |
Melting Point | 235℃ (Decomposition) |
Boling Point | 436.08°C (rough estimate) |
Flash Point | >110°(230°F) |
Water Solubility | Soluble in water at 50mg/ml. May require heating |
Solubility | H2O: 50 mg/mL, clear, slightly yellow |
Appearance | Morphological liquid |
Color | White |
BRN | 93902 |
pKa | 13.26±0.70(Predicted) |
Storage Condition | Keep in dark place,Inert atmosphere,2-8°C |
Stability | Stable for 1 year as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 2 months. |
Refractive Index | 1.7000 (estimate) |
MDL | MFCD00063462 |
Physical and Chemical Properties | Bioactive Puromycin aminonucleoside (NSC 3056) is an aminonucleoside antibiotic and a puromycin analog. Puromycin aminonucleoside induces apoptosis (apoptosis). Puromycin aminonucleoside reversibly inhibit dipeptidyl peptidase (dipeptidyl peptidase II) and cytosolic alanine aminopeptidase. Puromycin aminonucleoside is the aminonucleoside part of the antibiotic puromycin. |
Risk Codes | 48/22 - Harmful danger of serious damage to health by prolonged exposure if swallowed. |
WGK Germany | 3 |
RTECS | AU7337000 |
FLUKA BRAND F CODES | 10-21 |
TSCA | Yes |
HS Code | 29419090 |
Raw Materials | 3'-Azido-3'-deoxy-N6,N6-dimethyladenosine |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.398 ml | 16.989 ml | 33.978 ml |
5 mM | 0.68 ml | 3.398 ml | 6.796 ml |
10 mM | 0.34 ml | 1.699 ml | 3.398 ml |
5 mM | 0.068 ml | 0.34 ml | 0.68 ml |
EPA chemical information | Adenosine, 3'-amino-3'-deoxy-N,N-dimethyl- (58-60-6) |
in vitro studies
Puromycin aminonucleoside (NSC 3056) (30 μg/mL) markedly increases p53 protein levels in podocytes. Puromycin aminonucleoside (NSC 3056)-induced podocyte apoptosis is p53 dependent. Puromycin aminonucleoside (NSC 3056) induces podocyte apoptosis in a time-dependent manner. The IC 50 values for PMAT-expressing and vector-transfected cells are 48.9 and 122.1 μM, respectively, suggesting expression of PMAT-enhanced cell sensitivity to Puromycin aminonucleoside. Puromycin aminonucleoside (NSC 3056) (250 μM) is toxic to both PMAT-expressing and vector-transfected cells. Puromycin aminonucleoside (NSC 3056) uptake in PMAT-expressing cells is fourfold higher at pH 6.6 than that at pH 7.4.
In vivo studies
The number of podocytes per glomerulus is 95.5±17.6 in the control rats, 90.7 on Day 4 in Puromycin aminonucleoside (NSC 3056) (8 mg/100 g, I .v.)-treated nephrosis rats. The amount of nephrin per glomerulus in control rats is 1.02±0.11 fmol and those in Puromycin aminonucleoside (NSC 3056) nephrosis rats are reduced to 0.46±0.06 fmol and 0.35±0.04 fmol on Day 4 and Day 7. The nephrin amount per podocyte is significantly decreased association with the development of proteinuria in Puromycin aminonucleoside (NSC 3056) nephrosis rats. Rats given Puromycin aminonucleoside (NSC 3056) (100 mg/kg, s.c.) gain less weight and their serum creatinine levels are higher than the control rats.
category
Toxic substances
flammability hazard characteristics
Combustible; combustion produces toxic nitrogen oxide smoke
storage and transportation features
Warehouse ventilation low temperature drying
Fire extinguishing agent
Dry powder, foam, sand, carbon dioxide, mist water